DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

RBC Capital Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $11

RBC Capital analyst Kennen MacKay maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $14 to $11.

Benzinga · 03/18/2020 10:33

RBC Capital analyst Kennen MacKay maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $14 to $11.